<br>        Inclusion Criteria:<br><br>          -  Metastatic disease or locally advanced, unresectable disease.<br><br>               -  Has histopathologically confirmed gastric or GEJ adenocarcinoma with documented<br>                  disease progression after 0-2 prior lines of systemic therapy<br><br>               -  Has histopathologically confirmed nonsquamous or squamous NSCLC with documented<br>                  disease progression after 0-3 prior lines of systemic therapy<br><br>               -  Has histopathologically confirmed transitional cell carcinoma of the urothelium<br>                  (bladder, urethra, or renal pelvis) with documented disease progression after 1-3<br>                  prior lines of systemic therapy<br><br>               -  Has histologically confirmed biliary tract adenocarcinoma with documented<br>                  progression after 1-2 prior lines of systemic therapy<br><br>          -  Availability of tumor tissue for biomarker analysis from a newly obtained core or<br>             excisional biopsy or willing to undergo a tumor biopsy. For first line NSCLC<br>             participants only, PD-L1 expression should be 1% or higher.<br><br>          -  Have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.<br><br>          -  Has adequate organ function.<br><br>          -  Have an anticipated life expectancy of =3 months.<br><br>        Exclusion Criteria:<br><br>          -  Have known brain metastases.<br><br>          -  Has received =3 lines of prior systemic therapy for gastric or GEJ adenocarcinoma and<br>             BTC or =4 lines for NSCLC or urothelial cancer.<br><br>          -  Has active autoimmune disease.<br><br>          -  Known human immunodeficiency virus (HIV) infection.<br><br>          -  Known active hepatitis B or hepatitis C infection.<br><br>          -  Has received any previous systemic therapy targeting vascular endothelial growth<br>             factor (VEGF) or VEGF receptor, or programmed death (PD) 1 or PD-ligand 1/2 signaling<br>             pathways.<br><br>          -  Have received a live vaccine within 30 days prior to enrollment. Seasonal flu vaccines<br>             that do not contain live virus are permitted.<br><br>          -  Have had a serious or non-healing wound, ulcer, or bone fracture within 28 days prior<br>             to enrollment.<br><br>          -  Have an elective or a planned major surgery during the course of the trial or has<br>             undergone major surgery within 28 days prior to enrollment.<br>